Glaucoma is one of the most common causes of blindness worldwide, and its prevalence is
increasing. The aim of the present review is to describe the current medical and surgical …

Although once daily anti-glaucoma drug therapy is a current clinical reality, most therapies
require multiple dosing and there is an unmet need to develop convenient, safe, and …

Glaucoma is a group of diseases involving the optic nerve and associated structures, which
is characterized by progressive visual field loss and typical changes of the optic nerve head …

Glaucoma is a medical term describing a group of progressive optic neuropathies
characterized by degeneration of retinal ganglion cells and retinal nerve fibre layer and …

Damage to the optic nerve and the death of associated retinal ganglion cells (RGCs) by
elevated intraocular pressure (IOP), also known as glaucoma, is responsible for visual …

Introduction New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that
reduce treatment burden and improve outcomes relative to currently available agents are …

Glaucoma is a multifactorial neurodegenerative disorder and one of the leading causes of
irreversible blindness globally and for which intraocular pressure is the only modifiable risk …

Reduction of intraocular pressure is the only proven method to treat glaucoma. Initial
treatment of glaucoma commonly involves using anti-glaucoma medications either as …

We are pleased to bring you the 5th edition of the Glaucoma Clinical Practice Guidelines.
Clinical practice guidelines are based on evidence (scientific grounds). It is a document that …

Prostaglandin (PG) receptors represent important druggable targets due to the many diverse
actions of PGs in the body. From an ocular perspective, the discovery, development, and …